Tuesday, May 31, 2022

QualityStocksNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Major Step in Advancement of CYB003 for the Treatment of Major Depressive Disorder

 Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). According to the update, the IND is for Cybin’s phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, for the treatment of major depressive disorder (“MDD”). “Following the successful completion of our IND-enabling work just last month, we are very excited to have reached this major milestone toward advancing CYB003 into clinical development so quickly. Based on preclinical studies, our proprietary psilocybin analog has the potential to offer numerous advantages over classic psilocybin with the potential to ultimately provide better outcomes for people suffering with MDD,” said Cybin CEO Doug Drysdale. “This FDA submission is the next major step in the advancement of CYB003, and we continue to work tirelessly to bring this innovative therapeutic option to people as quickly as possible. We look forward to continuing to work with the FDA to initiate the phase 1/2a trial in mid-2022.”

To view the full press release, visit https://ibn.fm/Jj2fN

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Playgon Games Inc. (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR) Releases Q1 2022 Financial Report

 Playgon Games (TSX.V: DEAL) (OTCQB: PLGNF) (FSE: 7CR), a propriety SaaS technology company delivering mobile-first live-dealer technology to online gaming operators globally, is reporting its first quarter 2022 financial numbers; the report is for the quarter ended March 31, 2022. Highlights of the report include company revenues of $140,877, which came from Playgon’s Live Dealer platform. The company noted that it saw increased player betting throughout the quarter, a strong indicator for future revenue growth. In addition, Playgon observed an increase in player win percentage resulting in reduced house margins. The company also reported loss for the quarter of $3,899,555, a slight increase from its March 31, 2021, number; Playgon also had cash on hand of $2,486,326 at the end of the quarter. In addition, operational highlights for the quarter included Playgon entering into a multijurisdictional software licensing and distribution agreement with Relax Gaming, its fourth European aggregator. The company also onboarded nine additional operators, bringing total operator count to 35, and appointed  industry veteran Bobby Soper to its board of directors. “Q1 was another important quarter for Playgon,” said Playgon Games CEO Darcy Krogh in the press release. “We continued to see increased player activity throughout the quarter, and we exited with a healthy pipeline of new opportunities, which we expect to announce in due course. This will include entry into new markets for the company’s innovative mobile live dealer product that we are excited to enter.”

To view the full press release, visit https://ibn.fm/Csrf3

About Playgon Games Inc.

Playgon is a SaaS technology company focused on developing and licensing digital content for the growing iGaming market. The company provides a multitenant gateway that allows online operators the ability to offer their customers innovative iGaming software solutions. Its current software platform includes Live Dealer Casino, E-Table games and Daily Fantasy Sports, which, through a seamless integration at the operator level, allows customer access without having to share or compromise any sensitive customer data. As a true business-to-business digital content provider, Playgon products are ideal turnkey solutions for online casinos, sportsbook operators, land-based operators, media groups and big database companies. For more information about the company, please visit www.Playgon.com

NOTE TO INVESTORS: The latest news and updates relating to PLGNF are available in the company’s newsroom at https://ibn.fm/PLGNF  

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

QualityStocksNewsBreaks – Eat Well Investment Group Inc. (CSE: EWG) (OTC: EWGFF) Shares Update on Filing of Audit, 2021 Financials

 Eat Well Group (CSE: EWG) (OTC: EWGFF)a publicly traded investment company, has released an update regarding the anticipated timelines for the filing of its audited annual financial statements for the year ended Nov. 30, 2021, as well as other required documents, including the related management’s discussion and analysis and certificates of its CEO and CFO. The announcement noted that additional delays have taken place, although the company and its auditors continue to work diligently to file the required documents as soon as possible. According to the most recent estimates, the company plans on filing the information by June 10, 2022. In the announcement, Eat Well Group reiterated that, under the current management cease trade order (“MCTO”) issued by the British Columbia Securities Commission, its chief executive officer and chief financial officer are not allowed to trade in securities of the company. The company also confirmed that there have been no material changes to the information contained in the default announcement originally issued in March; that there have been no failures by the company to fulfill its stated intentions with respect to satisfying the provisions of the alternative reporting guidelines under NP 12-203; that there has not been, nor is there anticipated to be, any specified default subsequent to the default which is the subject of the default announcement; and there is no other material information concerning the affairs of the company that has not been generally disclosed.

To view the full press release, visit https://ibn.fm/396av

About Eat Well Investment Group Inc.

Eat Well Group is a publicly traded investment company primarily focused on high-growth companies in the agribusiness, food-tech, plant-based, and environmental, social and governance (“ESG”) sectors. Eat Well Group’s management team has an extensive record of sourcing, financing and building successful companies across a broad range of industries and maintains a current investment mandate on the health/wellness industry. The team has financed and invested in early-stage venture companies for more than 25 years, resulting in unparalleled access to deal flow and the ability to construct a portfolio of opportunistic investments intended to generate superior risk-adjusted returns. For more information about the company, please visit www.EatWellGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to EWGFF are available in the company’s newsroom at https://ibn.fm/EWGFF

About QualityStocksNewsBreaks

QualityStocksNewsBreaks provide a rapid summary of corporate news that catch the attention of QualityStocks. QualityStocksBreaks are designed to keep investors up to date on important and breaking news in the small-cap and micro-cap markets. Spanning all industries, including energy, entertainment, telecommunications, healthcare, retail and more, these news breaks deliver opportunities the investment community may have missed. Whether it is earnings results, mergers and acquisitions, or any other market-moving news, our news breaks keep you in the know. QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Mullen Automotive Inc. (NASDAQ: MULN) Working to Alleviate Consumer Anxiety by Offering EVs with 600-Plus Mile Range

 

  • J.D. Power survey reports range was factor most cited in deciding what EV to buy
  • Mullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV space
  • Recognizing the critical role of battery and range in the success of an EV, Mullen is exploring other advanced battery technologies

One of the challenges preventing enthusiastic acceptance of electric vehicles is range anxiety, fear that an electric car will run out of battery or fuel before the driver can reach their destination or a charging station. The concern is valid — a January 2022 Energy.gov study reported that the median rage for EV last year was 234 miles (https://ibn.fm/tvIzU). Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle manufacturer, is focused on improving that number; the company is currently actively testing advanced battery technology which can provide a range of 600-plus miles on a full charge at the pack level (https://ibn.fm/4H957).

“When modern all-electric vehicles (‘EV’) were introduced in model year (‘MY’) 2011, there were four models available with ranges spanning from 63 to 94 miles with a median range of 68 miles,” reports Energy.gov. “Over time, the number of models and the ranges of EVs have increased. By MY 2021, the maximum range for an EV had more than quadrupled to 405 miles on a single charge, while the median range was 234.”

This range limitation is causing concern for consumers. Forbes Wheel reports that in a 2021 J.D. Power survey, range was the factor most cited in deciding what EV to buy (https://ibn.fm/qx4Yy), and a ScienceABC article noted that more than 80% of consumers were hesitant to buy an electric vehicle because of range anxiety, along with the higher purchase cost (https://ibn.fm/cl3Om). “We have grown accustomed to conventional internal combustion engine (‘ICE’) vehicles for more than a century,” the article states. “Thus, there is a robust network of gas stations in most countries. In the US, an average American is just four minutes away from a gas station. Meanwhile, an average American lives 30 minutes away, on average, from a Tesla charging station. Tesla accounts for nearly 80% of electric car sales in the US, so looking at the statistics, the development of range anxiety is unsurprising.”

Mullen is making significant strides toward producing vehicles that feature some of the longest ranges available in the EV space, thereby alleviating range anxiety for potential EV buyers. Earlier this year, the company announced an update on its next-generation solid-state polymer battery technology, which is a significant advancement over today’s current lithium-ion batteries. 

“Mullen’s testing of solid-state polymer cells reveals the potential for a 150-kilowatt-hour battery pack that delivers over 600-plus miles of range and highlights an 18-minute DC fast charge which can yield over 300 miles of range,” the announcement says. “Mullen is working towards utilizing solid-state polymer battery packs in its second-generation Mullen FIVE EV Crossovers, with in-vehicle prototype testing set for 2025.”

Recognizing the importance of battery and range in the success of an EV, Mullen is also exploring other advanced battery technologies, including lithium-sulfur and lithium-iron-phosphate. The company is committed to do whatever is necessary to deliver EV batteries that will surpass today’s existing lithium-ion technology and offer a host of benefits, such as increased efficiency, energy density, and range, while also lowering the cost, weight, thermal and environmental risks.

“We’ve conducted successful testing and will begin pack level development next,” states Mullen CEO and chair David Michery. “The test data collected shows an impressive outcome and future for solid-state batteries. To sum up, we tested our 300 Ah (ampere-hour) cell, which yielded 343 Ah at 4.3 volts, and the results surpassed all expectations. We can say with almost certainty that this technology, once implemented on the Mullen FIVE, will deliver over 600 miles of range on a full charge. The future is bright for Mullen Automotive.” 

Mullen is a Southern Californian automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

For more information about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) and Kernel Report Result of Study Measuring Ketamine’s Effects on the Brain

 

  • Study shows that COVID-19 pandemic has affected mental health of 59% of U.S. population, intensifying already-serious issue
  • CYBN-sponsored feasibility study indicates ketamine-induced changes in brain’s functional connectivity persisted for several days after receiving the substance
  • Kernel Flow pivotal in developing most accurate, effective treatment regimens for patients

The challenges associated with mental-health issues are rising, following the global pandemic. Already a serious problem before COVID-19, mental health has become even more pressing now, with many companies committed to offering relief to the nearly 1 billion people worldwide who deal with mental-health issues. Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to progressing psychedelics to therapeutics, is making major progress in that direction based on pilot results from a recent study evaluating a proprietary neuroimaging technology (https://ibn.fm/1vach).

“In our national survey on mental health and coronavirus, we found that the COVID-19 pandemic has affected the mental health of 59% of people in the United States,” reported a recent SingleCare article (https://ibn.fm/IBtft). “Dismantling the stigma around mental illness is important now more than ever.”

SingleCare reported that an estimated 970 million people worldwide have a mental-health or substance-abuse disorder, with anxiety being the most common mental illness in the world, impacting 284 million people. Other significant mental-health challenges that are leading causes of serious disabilities include major depression, anxiety, alcohol-use disorders, schizophrenia, bipolar disorder, and dysthymia, or persistent mild depression. 

Cybin has joined the ranks of companies dedicated to finding and offering effective solutions to those suffering from mental health conditions. Most recently the company announced that pilot results from its sponsored feasibility study evaluating Flow, Kernel’s quantitative neuroimaging technology, indicate that ketamine-induced changes in the brain’s functional connectivity persisted for several days after receiving the substance. 

“Kernel’s Flow technology is revolutionary in the field of brain imaging as it is the first easy-to-use wearable that can collect real-time brain activity before, during and after a psychedelic experience,” said Doug Drysdale, Chief Executive Officer of Cybin. “Previously, studies had to rely on subjective patient reporting. By utilizing Flow, we will now be able to quantifiably gather real-time functional brain activity during our clinical and research studies evaluating psychedelic-based therapeutics.

“Measuring where and how psychedelics work in the brain unlocks new frontiers of discovery in this space,” continued Drysdale. “Most importantly, Kernel Flow will enable us to measure the duration of effect during a psychedelic experience, which will be pivotal in developing the most accurate and effective treatment regimens for patients. This technology is precisely what we need to accelerate the development of psychedelics into therapeutics.”

The purpose of the four-week study is to evaluate the altered state of consciousness of an individual following the administration of ketamine. The Kernel Flow headset facilitates this; the system is equipped with hi-tech sensors that record brain activity and report a participant’s experience using structured questionnaires and validated assessments during study visits and at follow-up. Cybin and Kernel signed a partnership agreement in January 2021 that gives Cybin exclusive interest in any innovations discovered or developed through the company’s independent analysis of the study findings, while Kernel retains the same rights relating to its Kernel technology.

“Kernel Flow is a groundbreaking neuroimaging technology that enables rigorous characterization and quantification of physiological processes in the human brain,” said Kernel founder and CEO Bryan Johnson. “We’re excited to report the pilot results of a longitudinally rich dataset of brain activity before, during a ketamine-induced altered-state experience, and after. The quality of the data recorded with Flow may lead to a better understanding of the neuro effects from psychedelics on the brain and help to advance these powerful new therapies for patients.”

Cybin is currently working on three active drug programs: CYB003 targets major depressive disorder and alcohol use disorder, CYB004 is focused on anxiety disorders and CYB005 is studying neuroinflammation. The company has completed more than 140 preclinical studies and is making steady progress toward FDA IND filings; in addition, Cybin has developed 50 novel compounds and completed more than 10 patent filings across three patent families. 

The company is collaborating with a network of world-class partners and internationally recognized scientists as it progresses on its mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. 

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php

Odyssey Group International Inc. (ODYY) Is ‘One to Watch’

 

  • Odyssey boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices
  • The company is evaluating PRV-002 for the treatment of concussion, a dramatically underserved indication that currently has no FDA-approved drug
  • With PRV-001, Odyssey aims to receive Orphan Drug designation, which could potentially accelerate its pathway to FDA approval and provide seven years of market exclusivity
  • CardioMap(R) is intended to provide early, non-invasive testing for heart disease and is being developed for a 510(k) regulatory pathway
  • Save-A-Life is a developmental anti-choking device that Odyssey expects to position as the “accepted” standard and leader in the treatment of choking incidents
  • The company’s sports advisory board is headlined by NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach
  • Odyssey is guided by a senior management team with significant experience relating to refining acquired technologies, building commercial systems and forging strategic partnerships

Odyssey Group International (OTC: ODYY) is a medical technology company focused on developing lifesaving medical products that offer technological and clinical advantages over current standards of care.

The company’s portfolio of product technologies is diverse, featuring four unique medical products in development. Odyssey’s goal is to deliver superior products with enhanced clinical utility and market potential, thereby yielding a high rate of return for its shareholders and partners. It is guided by a senior management team with significant experience relating to refining technologies, building commercial systems and forging strategic partnerships.

Product Portfolio

Pharmaceuticals

Odyssey has two pharmaceutical products in development:

  • PRV-002 is a novel compound for the treatment of concussion, which currently has no FDA-approved drug. In pre-clinical studies, PRV-002 has been shown to significantly improve both neuroscore and memory score following injury in rats subjected to concussion models. Importantly, the first-in-class novel neurosteroid demonstrated no drug-related toxicity in these trials.

PRV-002 is currently being evaluated in a phase I clinical trial for the treatment of concussion, with phase II trials planned for launch in Fall 2022. Odyssey has also highlighted the potential of PRV-002 for additional indications such as Alzheimer’s disease, Parkinson’s disease, ALS and chromic traumatic encephalopathy (“CTE”).

  • PRV-001 is a novel compound intended to treat Niemann-Pick disease, a rare neurodegenerative-lysosomal storage disorder that affects an estimated 1 in 150,000 individuals in the U.S., demonstrating a 5x higher incidence in Middle Eastern populations.

Odyssey expects to receive Orphan Drug designation from the FDA for PRV-001, which would accelerate its pathway to FDA approval and provide seven years of market exclusivity.

Medical Devices

Odyssey is also developing two medical device candidates:

  • CardioMap(R) is intended to provide early, non-invasive testing for heart disease. The system offers a number of potential advantages over traditional EKGs, including requiring less training to operate, offering heightened sensitivity and coming in a small and portable form factor. CardioMap is being developed for a 510(k) regulatory pathway, which requires a study to demonstrate equivalence to legacy EKG offerings.

When approved, CardioMap is expected to be the only device in its class that has a predictive value, illustrating ‘grey’ areas where deterioration has begun but not yet led to pathology. Odyssey expects this feature to provide a powerful incentive for doctors to use the CardioMap device in end markets such as hospitals, doctors’ offices, rehabilitation centers and sports medicine practices.

  • Save-A-Life (“SAL”) is a patented, single-action, instantaneous, handheld, mechanical anti-choking device that creates a vacuum chamber in the mouth to dislodge throat obstructions in a matter of seconds, all without harm to the victim. The device is currently in development, with a proof of concept established.

Odyssey believes that, once FDA-approved, its anti-choking device will quickly become the “accepted” standard and leader in the treatment of choking incidents globally. Its low-cost manufacturing and convenient portable design give SAL a competitive edge over competing devices utilizing cumbersome masks.

Market Opportunities

Odyssey’s varied development pipeline positions it to address a number of sizable market opportunities with significant unmet medical need. Concussions alone currently account for medical costs of roughly $10-15 billion annually in the U.S., despite the lack of a currently approved FDA drug treatment. This need is particularly apparent in the military and sports industry, where the likelihood of athlete head-injury recurrence is estimated at 75%.

It is for this reason that, in March 2021, Odyssey announced the formation of a sports advisory board featuring well-known athletes supporting the company’s efforts to enhance public awareness of traumatic brain injuries and concussions, as well as the need for an FDA-approved therapy. Members of Odyssey’s sports advisory board include NFL Hall of Famers Kurt Warner & Brett Favre and two-time Olympic gold medalist Abby Wambach.

With its CardioMap platform, Odyssey is targeting the global cardiac monitoring market, which was valued at $28 billion in 2021 by Insight Partners and forecast to reach $43 billion by 2028.

Save-A-Life targets a similarly underserved market. Choking is the fourth-leading cause of death in children, and approximately 5,000 choking deaths occur each year in the U.S. While 95% of these deaths result from in-home incidents, current choking rescue devices fail to address in-home applications.

Management Team

Joseph Michael Redmond is the President, CEO and Chairman of Odyssey. He has over 30 years of commercial experience in medical device companies, previously serving as CEO of Parallax Health Sciences Inc., V.P. of Business Development for DxTech Inc. and V.P. of Sales and Marketing for Bioject Medical Technologies Inc. While at Bioject, Mr. Redmond helped raise over $15 million in capital, entered into several licensing and distribution deals with major biotech and pharmaceutical companies and grew the market cap of the company from under $10 million to over $400 million. He started his career at Abbott Labs and holds a B.A. from Denison University.

Christine M. Farrell is the company’s CFO and Secretary. Prior to joining Odyssey, Ms. Farrell was Vice President of Finance for Bioject Medical Technologies Inc. She also held accounting and financial management positions with Spar-Tek Industries, a manufacturer of high quality and cutting-edge technology for the plywood industry, and Action Machinery, a seller of new and used robotic machine tools and equipment. Ms. Farrell holds a B.A. in Accounting from the University of Washington and an M.B.A. from Willamette University.

Dr. Jacob W. Vanlandingham is Odyssey’s Head of Drug Development. Dr. Vanlandingham holds a Ph.D. in neuroscience with a molecular biology focus. He is a member of the Society for Neuroscience, American Society for Nutritional Sciences, National Neurotrauma Society, Faculty for Undergraduate Research in Neuroscience and the International Association of Medical Science Educators.

For more information, visit the company’s website at 

NOTE TO INVESTORS: The latest news and updates relating to ODYY are available in the company’s newsroom at https://ibn.fm/ODYY 

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.

QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com

Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php